Results

Total Results: 685 records

Showing results for "cardiovascular".
Users also searched for: statin

201. March 3rd Impact of Healthcare Algorithms on Racial and Ethnic Disparities in Healthcare (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/impact-healthcare-algorithms-racial-ethnic-disparities-March-3.pdf
     July 01, 2023 - 13 KQ 2: Clinical Topics Cardiovascular risk Healthcare costs of utilization Intensive care … disease risk CHA2DS2-VASc for stroke risk Added biological input variables 3 ASCVD for cardiovascular … disease risk Novel risk prediction algorithm for cardiovascular disease COAG for warfarin dosing … for complex healthcare needs Recalibrated after improving population representation 4 ASCVD for cardiovascular … misuse Statistical techniques 2 Novel risk prediction algorithm for postpartum depression ASCVD for cardiovascular

202. Topic 0315 Disparities and SMI NSD SJ clean (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND-0373-14083.pdf
     July 09, 2014 - Population(s): Patients with SMI, with or without comorbid medical conditions such as diabetes, HIV and cardiovascular

203. Effective Health Care (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0262_05-11-2007.pdf
     January 01, 2007 - irritable bowel syndrome (IBS), diarrhea, constipation, and inflammatory bowel diseases (IBD)  Cardiovascular

204. Topic 0484 Treatments for Fecal Incontinence NSD FINAL SJ (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND-0572-140408.pdf
     January 09, 2014 - Cardiovascular and pulmonary conditions q.

205. Disposition of Comments for Use of Natriuretic Peptide Measurement in the Management of Heart Failure (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/heart-failure-natriuretic-peptide_disposition-comments.pdf
     November 20, 2013 - further clarification as follows: “as these have been shown to be associated with mortality from cardiovascular … disease and should thus be accounted for in all-cause mortality and cardiovascular specific mortality … Rev 3 General The established risk factors are for the prediction of the development of cardiovascular … evaluate the predictive strength of BNP/NTproBNP with respect to mortality outcomes (all cause and cardiovascular … The Protect study was not included as it was unclear whether the reported of death as cardiovascular

206. Breast-Cancer-Medications Surveillance (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/breast-cancer-medications_surveillance.pdf
     July 01, 2012 - 15-11 or 12 or 13 or 14 16-8 and 15 17-9 and 15 18-10 and 15 26 19-16 or 17 or 18 20-exp Cardiovascular … ============================================================== Medline on OVID – Search 7 1-exp cardiovascular … system/ 2-exp cardiovascular diseases/ 3-(cardiovascular or heart or cardiac).mp. 4-exp tamoxifen … ============================================================== Medline on OVID –Search 8 1-exp cardiovascular … system/ 2-exp cardiovascular diseases/ 3-(cardiovascular or heart or cardiac).mp. 4-exp tamoxifen

207. Point-Of-Care Research (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/point-of-care_research.pdf
     April 01, 2014 - Dietary Supplements in Adults Taking Cardiovascular Drugs. … Interactions of commonly used dietary supplements with cardiovascular drugs: a systematic review. … Dietary Supplements in Adults Taking Cardiovascular Drugs. … Interactions of commonly used dietary supplements with cardiovascular drugs: a systematic review. … Interactions of commonly used dietary supplements with cardiovascular drugs: a systematic review.

208. Clinical Effectiveness of Coronary Stents in the Elderly: Results From 262,700 Patients in the American College of Cardiology-National Cardiovascular Data Registry | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/coronary-stents-outcomes/research

209. Disposition of Comments Report for Antiplatelet and Anticoagulant Treatments for Unstable Angina/Non-ST Elevation Myocardial Infarction (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/angina-heart-attack-treatments_disposition-comments.pdf
     January 01, 2014 - Revise to: At 30 days, prasugrel reduced rates of cardiovascular death/myocardial infarction/stroke … associated with lower composite ischemic endpoints and individual endpoints (all-cause mortality, cardiovascular … associated with lower composite ischemic endpoints and individual endpoints (all-cause mortality, cardiovascular … Composite of cardiovascular mortality, nonfatal MI, or nonfatal stroke after 1 year- The event rates … The FDA approved BRILINTA™ (ticagrelor) Tablets to reduce the rate of thrombotic cardiovascular events

210. Diabetes Mellitus (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/diabetes-horizon-scan-high-impact-1406.pdf
     September 26, 2014 - According to the company, FDA requested additional cardiovascular data from a dedicated cardiovascular … in patients with T2DM at high risk of cardiovascular events. … According to the company, FDA requested additional cardiovascular data from a dedicated cardiovascular … insulin glargine in patients with T2DM at high risk of cardiovascular events. … Some experts expressed concerns about the potential for cardiovascular risks.

211. Prioritization and Selection of Harms for Inclusion in Systematic Reviews (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/ehc-presentation-selection-harms-systematic-reviews.pdf
     February 01, 2018 - blood pressure or low density lipoprotein concentrations is strongly associated with increased risk of cardiovascular … harms define the incidence of people experiencing one of several possible harms such as Major Adverse Cardiovascular … Events (MACE), comprising myocardial infarction, stroke, cardiovascular death, or target vessel revascularization … incidence of people experiencing one of several possible harms such as myocardial infarction, stroke, or cardiovascular

212. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/migraine-emergency_research-protocol.pdf
     July 18, 2011 - comorbidities including major depressive disorder, bipolar disorder, anxiety and social phobias, cardiovascular … Migraine and cardiovascular disease: a population-based study. Neurology 2010;74(8):628-35. … Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 2009;339:b3914. … Dodick D, Lipton RB, Martin V, et al, for the Triptan Cardiovascular Safety Expert Panel. … Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment

213. Disposition of Comments Report for Cardiac Troponins Used as Diagnostic and Prognostic Tests in Patients Wtih Kidney Disease (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/renal-function_disposition-comments.pdf
     August 11, 2014 - Page 15, KQ4—Is the increased cardiovascular risk associated with chronic kidney disease proportionate … Does this portend increased cardiovascular risk? … conclusions (no fault of the systematic review) is the lack of therapeutics that can be engaged to reduce cardiovascular … chronic elevation of cardiac troponin identifying patients with CKD who are at increased risk for cardiovascular … studies where the association of chronic troponin elevation is associated with increased risk for cardiovascular

214. Menopause-Protocol-130612 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/menopause-protocol-130612.pdf
     June 12, 2013 - owing in part to the results of observational studies interpreted to support a protective effect for cardiovascular … comparison of estrogen and progestin to placebo in the Women’s Health Initiative (WHI)—not only was cardiovascular … disease and cardiovascular events. … Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy … Vasomotor symptoms and cardiovascular events in postmenopausal women.

215. Data-Points-8 Tables1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/data-points-8_tables1.pdf
     January 01, 2009 - 78.8% 22.4 89.5% 2.0 1.3 Hyperlipidemia 2006 50.6 41.4 81.9% 40.2 79.6% 37.3 90.1% 2.1 1.3 Cardiovascular … 77.7% 34.9 88.9% 2.0 1.3 Hyperlipidemia 2007 86.4 70.8 82.0% 68.0 78.7% 63.2 89.2% 2.0 1.3 Cardiovascular … 78.3% 36.5 89.1% 2.0 1.3 Hyperlipidemia 2008 91.0 75.2 82.7% 71.9 79.0% 67.2 89.4% 2.0 1.3 Cardiovascular … 78.2% 37.6 88.7% 2.0 1.3 Hyperlipidemia 2009 94.9 79.0 83.2% 74.7 78.7% 70.1 88.7% 2.0 1.3 Cardiovascular … Hyperlipidemia 2006 14.6 35.2 7.0 17.0 12.8 31.0 16.2 39.0 18.7 45.1 3.7 8.9 0.8 1.8 0.1 0.1 11.3 27.3 Cardiovascular

216. Crosscutting-Horizon-Scan-High-Impact-1512 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/crosscutting-horizon-scan-high-impact-1512.pdf
     December 01, 2015 - This modeling technique can be used for any surgical procedure, but is most often used for cardiovascular … Materialise has listed its HeartPrint® cardiovascular models as Class I medical devices. … In a study (n=8) of 3-D printed cardiovascular models, Valverde et al. (2015) reported that surgeons … Under the program, patients who are undergoing major abdominal surgery (e.g., cardiovascular surgery … Valverde I, Gomez G, Suarez-Mejias C, et al. 3D printed cardiovascular models for surgical planning

217. Crosscutting-Horizon-Scan-High-Impact-1506 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/crosscutting-horizon-scan-high-impact-1506.pdf
     June 01, 2015 - Materialise has listed its HeartPrint® cardiovascular models as Class I medical devices. … In a study (n=8) of 3-D printed cardiovascular models published in 2015, Valverde et al. reported that … Under the MSHOP program, patients who are undergoing major abdominal surgery (e.g., cardiovascular … complications are enrolled in the program for about a month before major abdominal surgery (e.g., cardiovascular … Valverde I, Gomez G, Suarez-Mejias C, et al. 3D printed cardiovascular models for surgical planning

218. Diabetes-Drugs-Utilization Research (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/diabetes-drugs-utilization_research.pdf
     March 01, 2011 - rosiglitazone, a thiazolidine- dione, was found to be associated with myocardial infarction, major adverse cardiovascular … events, mortality from cardiovascular causes, and all-cause mortality.8 A more recent study comparing … Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

219. Template for Reports Developed (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/menopause_research-protocol.pdf
     March 25, 2012 - owing in part to the results of observational studies interpreted to support a protective effect for cardiovascular … comparison of estrogen and progestin to placebo in the Women’s Health Initiative (WHI)—not only was cardiovascular … disease and cardiovascular events. … Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy … Vasomotor symptoms and cardiovascular events in postmenopausal women. Menopause 2011;18(6):603-10.

220. Rheumatoid-Arthritis-Medicine Surveillance (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/rheumatoid-arthritis-medicine_surveillance.pdf
     March 01, 2013 - Biologics neither decreased nor increased cardiovascular risks in the elderly. … Those with high risk comorbidities (cardiovascular events, diabetes, malignancies, renal impairment … Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among … Biologics neither decreased nor increased cardiovascular risks in the elderly. … New Evidence: Those with highrisk comorbidities (cardiovascular events, diabetes, malignancies,